A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 1
60
about 4 years
18+
Male only
3 sites in SC, TX, VA
What this study is about
Researchers are testing the safety and how well valemetostat works when taken with darolutamide for people with metastatic castration-resistant prostate cancer. The trial will last about 1458 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Darolutamide
- 2.Take Valemetostat
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
darolutamide
oral (Oral Tablet)
Primary: Part 1 and 2: Number of Participants Experiencing a Treatment Emergent Adverse Event (TEAE)
Secondary: Objective Response Rate (ORR), Overall Survival (OS), Prostate-Specific Antigen (PSA) 50 Response Rate, Prostate-Specific Antigen (PSA) 90 Response Rate, Prostate-Specific Antigen (PSA) Nadir Response Rate, Radiographic Progression-Free Survival (rPFS)
Oncology